Impact of Aromatase Inhibitor Therapy on Bone Turnover, Cortical Bone Growth and Vertebral Morphology in Pre- and Peripubertal Boys with Idiopathic Short Stature

2009 ◽  
Vol 71 (5) ◽  
pp. 290-297 ◽  
Author(s):  
Matti Hero ◽  
Outi Mäkitie ◽  
Heikki Kröger ◽  
Elina Nousiainen ◽  
Sanna Toiviainen-Salo ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Aromatase Inhibitor ◽  
Short Stature ◽  
Cortical Bone ◽  
Bone Growth ◽  
Idiopathic Short Stature ◽  
Inhibitor Therapy ◽  
Aromatase Inhibitor Therapy

scholarly journals Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program

2020 ◽  
Vol 2020 (1) ◽  
Author(s):  
Bradley S. Miller ◽  
Judith Ross ◽  
Vlady Ostrow
Keyword(s):  
Growth Hormone ◽  
Aromatase Inhibitor ◽  
Growth Hormone Deficiency ◽  
Short Stature ◽  
Bone Age ◽  
Idiopathic Short Stature ◽  
Inhibitor Therapy ◽  
Hormone Deficiency ◽  
Aromatase Inhibitor Therapy ◽  
Epiphyseal Fusion

Abstract Background Treatment of children with growth hormone deficiency (GHD) or idiopathic short stature (ISS) using GH is only effective for bone growth prior to epiphyseal fusion. Aromatase inhibitor therapy (AIT) blocks estrogen production, thereby delaying epiphyseal fusion. The current study analyzed baseline characteristics and longitudinal data of male patients with GHD or ISS who were treated with GH and concomitant AIT. Methods Data were obtained from the observational American Norditropin® Studies: Web-Enabled Research (ANSWER) Program, which collected efficacy and safety data of patients treated with Norditropin®. A longitudinal cohort approach compared patient characteristics, including chronologic age, bone age, and height standard deviation score (HSDS), in GH-treated males before and after AIT initiation. Results A total of 142 GH-naïve patients with GHD (n = 115) or ISS (n = 27) with mean (± SD) baseline chronological ages of 12.10 ± 3.00 and 10.76 ± 3.07 years, respectively, were analyzed. The majority were classified at advanced Tanner stages II to V. Patients with GHD had mean HSDS of − 1.97 ± 0.78 at baseline and − 0.99 ± 0.88 prior to AIT initiation, while corresponding values for patients with ISS were − 2.15 ± 0.72 and − 1.04 ± 0.79, respectively. In patients evaluated after 2 years of concomitant AIT, mean HSDS had decreased to − 0.40 ± 1.16 and − 0.65 ± 0.52 for patients with GHD and ISS, respectively. Patients with GHD had a mean bone age/chronological age ratio (BA/CA) of 0.91 ± 0.11 at baseline and 0.97 ± 0.10 prior to AIT initiation, while corresponding values for patients with ISS were 0.85 ± 0.16 and 0.99 ± 0.10, respectively. In patients evaluated after 2 years of concomitant AIT, mean BA/CA values were 0.95 ± 0.10 and 0.96 ± 0.06 for patients with GHD and ISS, respectively. Conclusions In this real-world analysis, use of AIT with GH in males appeared to be associated with ongoing growth over 2 years, and AIT likely augmented growth potential as indicated by continued HSDS increase with decreased BA/CA after AIT initiation. Trial registration This trial was sponsored by Novo Nordisk and is registered with ClinicalTrials.gov (NCT01009905). Registered November 11, 2009; retrospectively registered

scholarly journals The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy

2021 ◽  
Vol 9 (4) ◽  
pp. 100378
Author(s):  
Nahid Punjani ◽  
Helen Bernie ◽  
Carolyn Salter ◽  
Jose Flores ◽  
Nicole Benfante ◽  
...  
Keyword(s):  
Aromatase Inhibitor ◽  
Inhibitor Therapy ◽  
Testosterone Therapy ◽  
Aromatase Inhibitor Therapy ◽  
Estradiol Levels
Sign in / Sign up

Export Citation Format

Share Document